Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 4/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL16968732 | 0.98 | DNM1 (0.47) | DNM1BBOX1APPBLMAPAF1 | |
| Hydrochloric Acid SCHEMBL30232595 | 0.98 | DNM1 (0.47) | DNM1BBOX1APPBLMAPAF1 | |
| SCHEMBL3504032 | 0.94 | DNM1 (0.52) | DNM1BBOX1APPBLMAPAF1 | |
| SCHEMBL17045025 | 0.92 | DNM1 (0.55) | DNM1BBOX1APPPSMD14PLA2G1B | |
| SCHEMBL918271 | 0.91 | BBOX1 (0.46) | DNM1BBOX1APPBLMLMNA | |
| SCHEMBL22115558 | 0.88 | DNM1 (0.45) | DNM1BBOX1APPHTT | |
| SCHEMBL22115570 | 0.88 | DNM1 (0.45) | DNM1BBOX1APPHTT | |
| SCHEMBL22115565 | 0.88 | DNM1 (0.45) | DNM1BBOX1APPHTT | |
| SCHEMBL22006989 | 0.86 | BBOX1 (0.43) | DNM1BBOX1APPPTGS1PDE4A | |
| SCHEMBL3505295 | 0.86 | DNM1 (0.41) | DNM1BBOX1APPBLMAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139755-B2 | Methods of RNA amplification | ASURAGEN, INC. (US) | 2024-11-12 | — | — | US | claimed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | claimed |
| WO-2024055011-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-03-14 | — | — | WO | claimed |
| US-11419333-B2 | Compositions and methods for biofilm removal | CHAMPIONX USA INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20220177949-A1 | METHODS OF RNA AMPLIFICATION | ASURAGEN, INC. | 2022-06-09 | — | — | US | claimed |
| US-11236384-B2 | Methods of RNA amplification | ASURAGEN, INC. (US) | 2022-02-01 | — | — | US | claimed |
| US-20200140923-A1 | METHODS OF RNA AMPLIFICATION | ASURAGEN, INC. | 2020-05-07 | — | — | US | claimed |
| US-20190223434-A1 | COMPOSITIONS AND METHODS FOR BIOFILM REMOVAL | HARBISON-FISCHER, INC. | 2019-07-25 | — | — | US | claimed |
| EP-2713163-B1 | Methods for isolating vesicles | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-05-08 | — | — | EP | claimed |
| US-20150291874-A1 | METHODS FOR MAKING AND USING NOVEL FOAMER COMPOSITIONS | WEATHERFORD TECHNOLOGY HOLDINGS, LLC | 2015-10-15 | — | — | US | claimed |
| WO-2009064719-A1 | IMIDAZOLINE-BASED HETEROCYCLIC FOAMERS FOR DOWNHOLE INJECTION | NALCO COMPANY (US) | 2009-05-22 | — | — | WO | claimed |
| US-20090131283-A1 | IMIDAZOLINE-BASED HETEROCYCLIC FOAMERS FOR DOWNHOLE INJECTION | PCS FERGUSON, INC. | 2009-05-21 | — | — | US | claimed |
| EP-1729794-B1 | A PHARMACEUTICAL COMPOSITION COMPRISING A NON-DETERGENT SULPHOBETAINE | LEK PHARMACEUTICALS (SI) | 2008-07-09 | — | — | EP | claimed |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | LEK PHARMACEUTICALS D.D. (SI) | 2007-08-09 | — | — | US | claimed |
| EP-1729794-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK Pharmaceuticals D.D. (SI) | 2006-12-13 | — | — | EP | claimed |
| US-20050250666-A1 | Foamer/sulfur scavenger composition and methods for making and using same | WEATHERFORD/LAMB, INC. | 2005-11-10 | — | — | US | claimed |
| WO-2005060989-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-07 | — | — | WO | claimed |
| US-20050137114-A1 | environmentally friendly, biodegradable, nondepositing and high temperatures resistant aqueous foaming agents comprising a mixture of anionic, cationic and zwitterionic surfactants, used as drilling fluids | WEATHERFORD/LAMB, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005007895-A1 | METHODS AND KITS FOR OBTAINING NUCLEIC ACID FROM BIOLOGICAL SAMPLES | APPLERA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050009036-A1 | Methods and kits for obtaining nucleic acid from biological samples | APPLERA CORPORATION (US) | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190223434-A1 | COMPOSITIONS AND METHODS FOR BIOFILM REMOVAL | ALG1, FUT5, FUT6 | DNM1 292/4885BBOX1 529/4885APP 3259/4885 |
| US-11419333-B2 | Compositions and methods for biofilm removal | ALG1, FUT5, FUT6 | DNM1 292/4885BBOX1 529/4885APP 3259/4885 |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | SCN2B, SCN1B, SPTSSB | DNM1 1969/4885BBOX1 1678/4885APP 2443/4885 |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | DNM1 3814/4885BBOX1 3754/4885APP 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.